Sana Biotechnology (SANA) news
Recent news
Sana Biotechnology Inc: Q2 2026 cash position of $160.5 million; expected cash runway into mid-2027
Sana Biotechnology Inc. (NASDAQ: SANA) reported a Q2 2026 cash position of $160.5 million, reflecting a significant increase from Q1 2026 . This growth in liquidity is attributed to a combination of strategic equity financing and operational efficiency. The company’s pro forma cash position, which…
AInvest Wire · Aug 10, 2026Sana Biotech 2Q loss from operations $65.4M, est. loss $42.5M
AInvest Wire · Aug 10, 2026Sana Biotech 2Q adj loss/share 13c, est. loss/share 14c
AInvest Wire · Aug 10, 2026Sana Biotechnology: sale of ~$69M of shares via ATM facility
Sana Biotechnology, Inc. (Nasdaq: SANA) has completed a public offering of approximately $75.0 million in shares of its common stock and pre-funded warrants, with gross proceeds expected to be around $75.0 million before underwriting discounts and other expenses. The offering includes 20,895,522…
AInvest Wire · May 15, 2026Sana Biotech 1Q loss from operations $48.6M, est. loss $48.1M
AInvest Wire · May 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.